Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Cartesian Therapeutics (NAS:RNAC) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Cartesian Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
10.62
/
1.01
=
10.51
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cartesian Therapeutics Median PS Value Related Terms
Cartesian Therapeutics Median PS Value Historical Data
* Premium members only.
The historical data trend for Cartesian Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RNAC vs CNXU, GALT, SRZN: Median PS Value Comparison
For the Biotechnology subindustry, Cartesian Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cartesian Therapeutics Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cartesian Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Cartesian Therapeutics's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 18.0357.
Cartesian Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.056.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cartesian Therapeutics (RNAC) has a Median PS Value of $1.01 as of Aug. 25, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Cartesian Therapeutics and its competitors. According to the industry distribution chart, Cartesian Therapeutics ranks #276 out of 282 companies in the Biotechnology industry, placing it in the top 97.9%.
Is Cartesian Therapeutics' Median PS Value too high?
Cartesian Therapeutics' current Median PS Value is $1.01. The Biotechnology industry median Median PS Value is 0.63. Cartesian Therapeutics' value of $1.01 is 60.3% above this industry median. Based on the distribution chart, Cartesian Therapeutics ranks #276 out of 282 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cartesian Therapeutics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cartesian Therapeutics' Median PS Value compare to CNXU and GALT?
According to the Biotechnology industry distribution chart, Cartesian Therapeutics ranks #276 out of 282 companies for Median PS Value. This places Cartesian Therapeutics in the lower half of its industry. The industry median Median PS Value is 0.63. Cartesian Therapeutics' value of $1.01 is 60.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 282 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cartesian Therapeutics's current Median PS Value of $1.01 is 60.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Cartesian Therapeutics and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cartesian Therapeutics's current Median PS Value is $1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cartesian Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cartesian Therapeutics (RNAC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.29, compared to a current price of $10.62 — trading 3562.1% above its estimated fair value. The current Median PS Value is $1.01 and 60.3% above the Biotechnology industry median of 0.63. Cartesian Therapeutics' overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Cartesian Therapeutics (RNAC), the current Median PS Value is $1.01 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cartesian Therapeutics (RNAC) Overvalued in 2026?
Based on GuruFocus' analysis, Cartesian Therapeutics stock appears to be overvalued.
The current stock price of $10.62 is trading 3562.1% above its estimated GF Value™ of $0.29.
GuruFocus considers Cartesian Therapeutics to be Significantly Overvalued.
Key valuation signals for RNAC:
Median PS Value: $1.01
GF Value™: $0.29 vs. price of $10.62 (3562.1% above fair value)
Industry Position: 60.3% above the Biotechnology median (#276 of 282)
No single metric tells the full story. See the RNAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
24GF Score
Get the complete analysis for RNAC
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNAC has been successfully added to your 
